With De-Risking the Mantra, Novartis Expands Presence in RNAi: Narasimhan in Conversation

Why It Matters

RNAi expansion diversifies Novartis’ pipeline, reducing reliance on a single technology and positioning the firm to capture growth in a fast‑evolving therapeutic class.

Key Takeaways

• Novartis signed multiple RNAi licensing deals in 2025.
• In‑house RNAi pipeline targets liver and CNS diseases.
• De‑risking strategy emphasizes platform diversification over single‑shot bets.
• Radioligand and autoimmune CAR‑T programs remain revenue pillars.
• RNAi expansion positions Novartis against Alnylam and Dicerna.

Pulse Analysis

RNA interference has moved from academic curiosity to a commercial engine, with global sales projected to exceed $10 billion by 2030. Novartis’ recent de‑risking mantra reflects a broader industry trend: hedge bets across multiple modalities to smooth revenue volatility. By weaving RNAi into its existing platform strategy, the Swiss giant seeks to leverage its robust development infrastructure while avoiding the pitfalls of chasing a single breakthrough. This approach mirrors its earlier early‑adoption of radioligand therapies, which now generate a growing share of its oncology pipeline.

The company’s RNAi push is anchored by a series of 2025 licensing deals with specialist firms, granting access to proprietary siRNA delivery technologies and early‑stage candidates. Internally, Novartis has launched an RNAi discovery hub focused on hepatic and central‑nervous‑system targets, areas where delivery challenges are being mitigated by novel lipid nanoparticle platforms. Integrating RNAi with its radioligand and autoimmune CAR‑T programs creates cross‑modal synergies, allowing shared data on target validation, biomarker development, and manufacturing efficiencies. This multi‑track strategy aims to accelerate time‑to‑clinic while spreading risk across distinct therapeutic arenas.

For investors and competitors, Novartis’ RNAi expansion signals heightened competition for market share against dedicated RNAi players like Alnylam and Dicerna. The move could also reshape partnership dynamics, as the company now possesses both the capital and platform expertise to co‑develop or acquire promising candidates. If the pipeline delivers first‑in‑class approvals, Novartis could capture a sizable slice of the emerging RNAi market, reinforcing its reputation as a diversified, innovation‑driven pharma leader.